Pseudomyxoma Peritonei
Oncology·MeSH: Pseudomyxoma Peritonei
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Mitomycin c | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Pseudomyxoma Peritonei?
BioSniper tracks 1 drug in development for Pseudomyxoma Peritonei across 1 company.
How many clinical trials target Pseudomyxoma Peritonei?
There are 2 clinical trials targeting Pseudomyxoma Peritonei tracked by BioSniper.
What is the prevalence of Pseudomyxoma Peritonei?
The estimated prevalence of Pseudomyxoma Peritonei is approximately 5.0 per 100,000 population.
Deep-dive into Pseudomyxoma Peritonei
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis